Renal cell carcinoma (RCC) is one of the most common cancers in the United States. The most frequent form of RCC, clear cell RCC (ccRCC), is particularly aggressive with high mortality. Thus, there is an urgent need for prognostic tools and treatments. The protein Integrin β4 (ITGB4) plays important roles in other malignancies, but its role in ccRCC is not well documented. A recent study confirmed that ITGB4 was significantly overexpressed in ccRCC tissues and that high levels predicted metastasis and a poor prognosis. ITGB4 stimulated cell migration and invasion in benchtop experiments and metastasis in a mouse model. Another protein, methyltransferase-like 14 (METTL14), accelerated the degradation of ITGB4 mRNA, ultimately reducing ITGB4's expression. METTL14 did this by facilitating the addition of a methyl group to an adenosine on the end of ITGB4 mRNA. The modified ITGB4 mRNA is then bound by YTH domain family protein 2 (YTHDF2), which promotes the decay of the mRNA. Reducing expression of METTL14 also promoted ccRCC cell migration, invasiveness, and metastasis. These results suggest that the ITGB4-METLL14 axis has potential as a prognostic biomarker and therapeutic target.